BCI Press Kit

Direct all media inquires to pr@biotheranostics.com

BCI Product Information

Download

Current Press

Breast Cancer IndexSM Predicted Patients at High Risk of Recurrence Despite Low Risk Clinical Features, New Data Suggest

December 8, 2016 || San Diego, CA

…Results from new analyses of two cohorts demonstrate that Breast Cancer Index (BCI), a genomic biomarker performed by Biotheranostics, Inc. ...

Read More

New Data Substantiate the Ability of Breast Cancer IndexSM to Help Physicians Identify Early Stage ER+ Breast Cancer Patients for Extended Anti-Estrogen Therapy

December 8, 2016 || San Diego, CA

…Biotheranostics today announced that new data will be presented demonstrating the role of the Breast Cancer Index (BCI) in identifying which patients with early stage, ER+ breast cancer...

Read More

New Data Presented at 2016 ASCO Annual Meeting Expand Clinical Utility of Breast Cancer IndexSM in the Extended Adjuvant Setting to Include Early Stage, ER+ Patients with Up to Three Positive Nodes

June 6, 2016 || San Diego, CA

…Biotheranostics announced new independent data validating a new Breast Cancer Index (BCI) prognostic model specifically developed for ER+ breast cancer patients with 1‑3 positive...

Read More

Clinical Cancer Research Publishes Study Demonstrating Clinically Meaningful and Statistically Significant Prognostic Improvement by the Breast Cancer Index(SM) Over Oncotype DX® in Early-Stage, Estrogen Receptor-Positive, Lymph Node-Negative Breast Cancer Patients

June 2, 2016 || San Diego, CA

…Clinical Cancer Research, the official journal of the American Association for Cancer Research, reported results of an analysis within the Arimidex, Tamoxifen, Alone or...

Read More

Studies Demonstrate Broadening Clinical Utility of Biotheranostics’ Breast Cancer IndexMolecular Test in the Extended Endocrine Therapy Setting

December 8, 2015 || San Diego, CA

…Biotheranostics, a leader in molecular diagnostics for cancer, announced the results of several studies being presented at the San Antonio Breast Cancer Symposium this week...

Read More

Yale Study Shows Biotheranostics’ Breast Cancer IndexSM Molecular Test Impacts Extended Endocrine Therapy Decisions in Clinical Practice

December 7, 2015 || San Diego, CA

…In the first prospective assessment of the impact of Biotheranostics’ Breast Cancer IndexSM (BCI) molecular test in clinical practice, incorporation of BCI results led to treatment decision changes in 26 percent of patients...

Read More

Journal of the National Comprehensive Cancer Network Review Article Highlights Role of Biotheranostics’ Breast Cancer IndexSM in Optimizing Endocrine Therapy

September 16, 2015 || San Diego, CA

…A review article published in the Journal of the National Comprehensive Cancer Network examining the evolving evidence for optimization of endocrine therapy in breast cancer patients...

Read More

Studies Presented at 2015 ASCO Meeting Demonstrate Predictive Power of Biotheranostics’ Breast Cancer IndexSM Molecular Test in Endocrine Therapy Decisions

May 30, 2015 || Chicago, IL

…Biotheranostics, Inc., today announced results from studies being presented at the 2015 American Society of Clinical Oncology (ASCO) meeting reinforcing the role its Breast Cancer IndexSM (BCI) molecular test...

Read More

Study Underscores Value of Biotheranostics’ Breast Cancer IndexSM in Informing Decisions about Long-Term Endocrine Therapy & Assessing Risk of Late Recurrence

February 16, 2015 || Miami, FL

…Biotheranostics, Inc., today announced results from a study being presented at the 32nd Miami Breast Cancer Conference that further support the role of its Breast Cancer IndexSM (BCI) molecular test in assessing risk of late recurrence and determining which patients with early stage...

Read More

Studies Reinforce Unique Predictive and Prognostic Abilities of Biotheranostics’ Breast Cancer Index Molecular Test

December 9, 2014 || San Antonio, TX

…Results from three studies being presented at the 37th Annual San Antonio Breast Cancer Symposium this week underscore the unique abilities of Biotheranostics’ Breast Cancer IndexSM molecular test...

Read More

Biotheranostics Awarded Medicare Coverage for Breast Cancer IndexSM Molecular Test

October 15, 2014 || San Diego, CA

…Biotheranostics, Inc., a leader in molecular diagnostics for cancer, today announced that its Breast Cancer IndexSM test has been awarded Medicare coverage. The Centers for Medicare and Medicaid Services posted...

Read More
Read more articles
Breast Cancer Index Intended Use and Limitations

The Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test is intended for use in patients diagnosed with estrogen receptor-positive (ER+), lymph node-negative (LN-) or lymph node positive (LN+; with 1-3 positive nodes) early-stage, invasive breast cancer, who are distant recurrence-free. BCI provides: 1) a quantitative assessment of the likelihood of both late (post-5 years) and overall (0-10 year) distant recurrence following an initial 5 years of endocrine therapy (LN- patients) or 5 years of endocrine therapy plus adjuvant chemotherapy (LN+ patients), and 2) prediction of likelihood of benefit from extended (>5 year) endocrine therapy. BCI results are adjunctive to the ordering physician’s workup; treatment decisions require correlation with all other clinical findings.

This test was developed and its performance characteristics determined by Biotheranostics, Inc. lt has not been cleared or approved by the U.S. Food and Drug Administration. This test is used for clinical purposes. lt should not be regarded as investigational or for research. How this information is used to guide patient care is the responsibility of the physician. Biotheranostics is certified under the Clinical Laboratory lmprovement Amendments of 1988 to perform high complexity clinical laboratory testing.